264 related articles for article (PubMed ID: 29229835)
21. Tyrosine Kinase Signaling in Cancer Metabolism: PKM2 Paradox in the Warburg Effect.
Wiese EK; Hitosugi T
Front Cell Dev Biol; 2018; 6():79. PubMed ID: 30087897
[TBL] [Abstract][Full Text] [Related]
22. Interdependence of GLO I and PKM2 in the Metabolic shift to escape apoptosis in GLO I-dependent cancer cells.
Shimada N; Takasawa R; Tanuma SI
Arch Biochem Biophys; 2018 Jan; 638():1-7. PubMed ID: 29225125
[TBL] [Abstract][Full Text] [Related]
23. Elevated O-GlcNAcylation stabilizes FOXM1 by its reduced degradation through GSK-3β inactivation in a human gastric carcinoma cell line, MKN45 cells.
Inoue Y; Moriwaki K; Ueda Y; Takeuchi T; Higuchi K; Asahi M
Biochem Biophys Res Commun; 2018 Jan; 495(2):1681-1687. PubMed ID: 29196265
[TBL] [Abstract][Full Text] [Related]
24. PKM2 Promotes Cell Survival and Invasion Under Metabolic Stress by Enhancing Warburg Effect in Pancreatic Ductal Adenocarcinoma.
Li C; Zhao Z; Zhou Z; Liu R
Dig Dis Sci; 2016 Mar; 61(3):767-73. PubMed ID: 26500118
[TBL] [Abstract][Full Text] [Related]
25. PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the Warburg effect.
Dang CV
Sci Signal; 2009 Nov; 2(97):pe75. PubMed ID: 19920249
[TBL] [Abstract][Full Text] [Related]
26. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
[TBL] [Abstract][Full Text] [Related]
27. Role of PKM2 in directing the metabolic fate of glucose in cancer: a potential therapeutic target.
van Niekerk G; Engelbrecht AM
Cell Oncol (Dordr); 2018 Aug; 41(4):343-351. PubMed ID: 29797241
[TBL] [Abstract][Full Text] [Related]
28. Enzymatic activation of pyruvate kinase increases cytosolic oxaloacetate to inhibit the Warburg effect.
Wiese EK; Hitosugi S; Loa ST; Sreedhar A; Andres-Beck LG; Kurmi K; Pang YP; Karnitz LM; Gonsalves WI; Hitosugi T
Nat Metab; 2021 Jul; 3(7):954-968. PubMed ID: 34226744
[TBL] [Abstract][Full Text] [Related]
29. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours.
Mazurek S
Ernst Schering Found Symp Proc; 2007; (4):99-124. PubMed ID: 18811055
[TBL] [Abstract][Full Text] [Related]
30. Pyruvate kinase: Function, regulation and role in cancer.
Israelsen WJ; Vander Heiden MG
Semin Cell Dev Biol; 2015 Jul; 43():43-51. PubMed ID: 26277545
[TBL] [Abstract][Full Text] [Related]
31. SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions.
Keller KE; Tan IS; Lee YS
Science; 2012 Nov; 338(6110):1069-72. PubMed ID: 23086999
[TBL] [Abstract][Full Text] [Related]
32. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth.
Cortés-Cros M; Hemmerlin C; Ferretti S; Zhang J; Gounarides JS; Yin H; Muller A; Haberkorn A; Chene P; Sellers WR; Hofmann F
Proc Natl Acad Sci U S A; 2013 Jan; 110(2):489-94. PubMed ID: 23267074
[TBL] [Abstract][Full Text] [Related]
33. PKM2 Thr454 phosphorylation increases its nuclear translocation and promotes xenograft tumor growth in A549 human lung cancer cells.
Yu Z; Huang L; Qiao P; Jiang A; Wang L; Yang T; Tang S; Zhang W; Ren C
Biochem Biophys Res Commun; 2016 May; 473(4):953-958. PubMed ID: 27045080
[TBL] [Abstract][Full Text] [Related]
34. CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma.
Shang Y; He J; Wang Y; Feng Q; Zhang Y; Guo J; Li J; Li S; Wang Y; Yan G; Ren F; Shi Y; Xu J; Zeps N; Zhai Y; He D; Chang Z
Oncogene; 2017 Jul; 36(29):4191-4200. PubMed ID: 28346425
[TBL] [Abstract][Full Text] [Related]
35. TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma.
Chen Z; Wang Z; Guo W; Zhang Z; Zhao F; Zhao Y; Jia D; Ding J; Wang H; Yao M; He X
Oncogene; 2015 Jul; 34(30):3946-56. PubMed ID: 25263439
[TBL] [Abstract][Full Text] [Related]
36. Pyruvate kinase M2 and cancer: an updated assessment.
Iqbal MA; Gupta V; Gopinath P; Mazurek S; Bamezai RN
FEBS Lett; 2014 Aug; 588(16):2685-92. PubMed ID: 24747424
[TBL] [Abstract][Full Text] [Related]
37. O-GlcNAcylation: a bridge between glucose and cell differentiation.
Sun C; Shang J; Yao Y; Yin X; Liu M; Liu H; Zhou Y
J Cell Mol Med; 2016 May; 20(5):769-81. PubMed ID: 26929182
[TBL] [Abstract][Full Text] [Related]
38. Pyruvate kinase M2: regulatory circuits and potential for therapeutic intervention.
Gupta V; Wellen KE; Mazurek S; Bamezai RN
Curr Pharm Des; 2014; 20(15):2595-606. PubMed ID: 23859618
[TBL] [Abstract][Full Text] [Related]
39. The molecular mechanisms of LncRNA-correlated PKM2 in cancer metabolism.
Tao T; Wu S; Sun Z; Ma W; Zhou S; Deng J; Su Q; Peng M; Xu G; Yang X
Biosci Rep; 2019 Nov; 39(11):. PubMed ID: 31654067
[TBL] [Abstract][Full Text] [Related]
40. 2-Deoxyglucose induces the expression of thioredoxin interacting protein (TXNIP) by increasing O-GlcNAcylation - Implications for targeting the Warburg effect in cancer cells.
Hong SY; Hagen T
Biochem Biophys Res Commun; 2015 Oct; 465(4):838-44. PubMed ID: 26315267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
